Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142044 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
A Phase 1 study of Parkinson's Disease (PD), sponsored by EicOsis Human Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT07142044 is a Phase 1 study of Parkinson's Disease (PD) that is actively recruiting participants, run by EicOsis Human Health. The registered enrollment target is 18 participants, below the 53-participant average among 4 other Parkinson's Disease (PD) trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07142044, a Phase 1 study of Parkinson's Disease (PD), is actively recruiting participants, sponsored by EicOsis Human Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are: * Is EC5026 safe in adults with Parkinson's Disease? * What are the levels of EC5026 achieved after oral administration for 28 days? * What molecules or pathways does EC5026 target, and to what extent? In addition, although it is not one of the primary aims of the study, this clinical trial will also explore if oral administration of EC5026 improves the symptoms of Parkinson's Disease. Researchers will compare EC5026 to a placebo (a look-alike substance that contains no drug). Participants will: * Take EC5026 or a placebo every day for 28 consecutive days * Visit the clinic for frequent checkups, blood tests, spinal fluid tests, and questionnaires
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EC5026 oral tablet
Study Locations (1)
California
- University of California Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-10 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07142044
The ClinicalTrials.gov registry entry for NCT07142044 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 53-participant average among 4 other Parkinson's Disease (PD) trials with a reported enrollment target (66% lower). The listed sponsor is EicOsis Human Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease (PD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07142044 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07142044 about?
NCT07142044 is a clinical study titled "Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)". The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questi...
What is the current status of trial NCT07142044?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-10. Estimated completion is 2027-06.
What conditions does trial NCT07142044 study?
This clinical trial studies the following conditions: Parkinson's Disease (PD).
What interventions are being tested in trial NCT07142044?
The interventions under investigation include: Placebo (DRUG), EC5026 oral tablet (DRUG).
Who is sponsoring clinical trial NCT07142044?
This trial is sponsored by EicOsis Human Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142044 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients
RECRUITING · NA
-
Accelerated TMS for Freezing of Gait in Parkinson's Disease
RECRUITING · NA
-
Attention and Eye Movement in Parkinson's Disease
RECRUITING · NA
-
Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.